Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.9
4.9
Journals
Pharmaceutics
Special Issues
Development of Novel Nanomedicines for Combination Therapy and Theranostic Applications
share announcement

Development of Novel Nanomedicines for Combination Therapy and Theranostic Applications

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: closed (20 August 2022) | Viewed by 7123

Special Issue Editor

Dr. Amalia Ruiz

E-Mail Website
Guest Editor
Institute of Cancer Therapeutics, University of Bradford, Richmond Rd, Bradford BD7 1DP, UK
Interests: drug delivery systems; smart nanomaterials; nanotoxicology; hyperthermia; photothermal; photodynamic therapy; combination therapies and theragnostic applications

Special Issue Information

Dear Colleagues,

We are inviting you to contribute to this Special Issue dedicated to the development of nanotherapeutics for combination therapies and theranostic applications. Combination therapy is a cornerstone of cancer therapy; this method combines two or more therapeutic agents to enhance the efficacy of treatment compared to monotherapy. Multifunctional drug delivery systems have emerged as invaluable tools for the treatment of different types of cancer using this approach. Depending on their size, shape, composition, and functionalisation, they may be used for coloading different chemotherapeutic agents, active tumour targeting, as diagnostic tools, and as anticancer agents due to their physicochemical properties (magnetic nanomaterials, photothermal/photodynamic agents, radiosensitisers, etc). The development of combination therapies that include one or more anticancer agents that target different pathways is highly desirable. Additionally, understanding their pharmacokinetics, toxicokinetic, and biodegradation pathways is crucial to nanotherapeutics development and can help improve the safety profile of nanomedicines.

This Special Issue aims to highlight recent advances in the development of novel nanotherapeutics for combination therapy and theranostic applications in cancer treatment.

Original research articles and reviews are welcome for this Special Issue. Research areas may include (but are not limited to) the following:

  • Synthesis and characterisation of novel nanomaterials for combination therapies and/or theragnostic applications,
  • Multifunctionalisation strategies to develop novel theragnostic drug delivery systems,
  • Nanoformulations coloading different therapeutic agents,
  • Cell-based delivery systems for theranostic applications,
  • Novel nanosystems combining traditional chemotherapy with photothermal, photodynamic, radiotherapy, and immunotherapy,
  • Safety evaluation of novel nanotherapeutics for combination therapies.

I look forward to receiving your contributions.

Dr. Amalia Ruiz
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • combination therapy
  • cancer therapy
  • nanotherapeutics
  • nanotheranostics
  • photothermal therapy
  • photodynamic therapy
  • magnetic hyperthermia
  • multifunctional drug delivery systems
  • nanosafety
  • nanotoxicology

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

15 pages, 2686 KiB  
Article
Fine Control of In Vivo Magnetic Hyperthermia Using Iron Oxide Nanoparticles with Different Coatings and Degree of Aggregation
by Yurena Luengo, Zamira V. Díaz-Riascos, David García-Soriano, Francisco J. Teran, Emilio J. Artés-Ibáñez, Oihane Ibarrola, Álvaro Somoza, Rodolfo Miranda, Simó Schwartz, Jr., Ibane Abasolo and Gorka Salas
Pharmaceutics 2022, 14(8), 1526; https://doi.org/10.3390/pharmaceutics14081526 - 22 Jul 2022
Cited by 10 | Viewed by 2154
Abstract
The clinical implementation of magnetic hyperthermia has experienced little progress since the first clinical trial was completed in 2005. Some of the hurdles to overcome are the reliable production of magnetic nanoparticles with controlled properties and the control of the temperature at the [...] Read more.
The clinical implementation of magnetic hyperthermia has experienced little progress since the first clinical trial was completed in 2005. Some of the hurdles to overcome are the reliable production of magnetic nanoparticles with controlled properties and the control of the temperature at the target tissue in vivo. Here, forty samples of iron oxide superparamagnetic nanoparticles were prepared by similar methods and thoroughly characterized in terms of size, aggregation degree, and heating response. Selected samples were intratumorally administered in animals with subcutaneous xenografts of human pancreatic cancer. In vivo experiments showed that it is possible to control the rise in temperature by modulating the field intensity during in vivo magnetic hyperthermia protocols. The procedure does not require sophisticated materials and it can be easily implemented by researchers or practitioners working in magnetic hyperthermia therapies. Full article
(This article belongs to the Special Issue Development of Novel Nanomedicines for Combination Therapy and Theranostic Applications)
►▼ Show Figures

Figure 1

18 pages, 7181 KiB  
Article
Combined Photothermal and Photodynamic Therapy for Cancer Treatment Using a Multifunctional Graphene Oxide
by Shi Guo, Zhengmei Song, Ding-Kun Ji, Giacomo Reina, Jean-Daniel Fauny, Yuta Nishina, Cécilia Ménard-Moyon and Alberto Bianco
Pharmaceutics 2022, 14(7), 1365; https://doi.org/10.3390/pharmaceutics14071365 - 28 Jun 2022
Cited by 20 | Viewed by 2805
Abstract
Graphene oxide (GO) is one of the most studied nanomaterials in many fields, including the biomedical field. Most of the nanomaterials developed for drug delivery and phototherapies are based on noncovalent approaches that lead to an unspecific release of physisorbed molecules in complex [...] Read more.
Graphene oxide (GO) is one of the most studied nanomaterials in many fields, including the biomedical field. Most of the nanomaterials developed for drug delivery and phototherapies are based on noncovalent approaches that lead to an unspecific release of physisorbed molecules in complex biological environments. Therefore, preparing covalently functionalized GO using straightforward and versatile methods is highly valuable. Phototherapies, including photothermal therapy (PTT) and photodynamic therapy (PDT), have shown great potential as effective therapeutic approaches against cancer. To overcome the limits of a single method, the combination of PTT and PDT can lead to a combined effect with a higher therapeutic efficiency. In this work, we prepare a folic acid (FA) and chlorin e6 (Ce6) double-functionalized GO for combined targeted PTT/PDT. This conjugate can penetrate rapidly into cancer cells and macrophages. A combined effect of PTT and PDT is observed, leading to a higher killing efficiency toward different types of cells involved in cancer and other diseases. Our work provides a simple protocol to prepare multifunctional platforms for the treatment of various diseases. Full article
(This article belongs to the Special Issue Development of Novel Nanomedicines for Combination Therapy and Theranostic Applications)
►▼ Show Figures

Figure 1

Review

Jump to: Research

20 pages, 1918 KiB  
Review
The Recent Development of Multifunctional Gold Nanoclusters in Tumor Theranostic and Combination Therapy
by Sisi Liu, Junyao Wang, Yuxin Song, Shuya He and Huaxin Tan
Pharmaceutics 2022, 14(11), 2451; https://doi.org/10.3390/pharmaceutics14112451 - 14 Nov 2022
Cited by 3 | Viewed by 1714
Abstract
The rising incidence and severity of malignant tumors threaten human life and health, and the current lagged diagnosis and single treatment in clinical practice are inadequate for tumor management. Gold nanoclusters (AuNCs) are nanomaterials with small dimensions (≤3 nm) and few atoms exhibiting [...] Read more.
The rising incidence and severity of malignant tumors threaten human life and health, and the current lagged diagnosis and single treatment in clinical practice are inadequate for tumor management. Gold nanoclusters (AuNCs) are nanomaterials with small dimensions (≤3 nm) and few atoms exhibiting unique optoelectronic and physicochemical characteristics, such as fluorescence, photothermal effects, radiosensitization, and biocompatibility. Here, the three primary functions that AuNCs play in practical applications, imaging agents, drug transporters, and therapeutic nanosystems, are characterized. Additionally, the promise and remaining limitations of AuNCs for tumor theranostic and combination therapy are discussed. Finally, it is anticipated that the information presented herein will serve as a supply for researchers in this area, leading to new discoveries and ultimately a more widespread use of AuNCs in pharmaceuticals. Full article
(This article belongs to the Special Issue Development of Novel Nanomedicines for Combination Therapy and Theranostic Applications)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop